Screening, diagnosis and management of diabetes mellitus and diabetes-associated complications;Screening, Diagnostik und Management von Diabetes mellitus und diabetischen Folgeerkrankungen

Therapeutische Umschau

Volumn 57, Issue 1, 2000, Pages 12-20

  Lehmann, R ^a   Spinas, G A ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; GLUCOSE; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C; INSULIN; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PRAVASTATIN; SIMVASTATIN;

BLOOD PRESSURE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DISEASE CLASSIFICATION; DYSLIPIDEMIA; GLUCOSE BLOOD LEVEL; HUMAN; ORAL GLUCOSE TOLERANCE TEST; REVIEW; SCREENING;

ADULT; AGED; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DIABETES, GESTATIONAL; FEMALE; GLUCOSE TOLERANCE TEST; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; MALE; MASS SCREENING; MIDDLE AGED; PREGNANCY; RISK FACTORS;

EID: 0033972006     PISSN: 00405930     EISSN: None     Source Type: Journal    
DOI: 10.1024/0040-5930.57.1.12     Document Type: Article

References (43)

1. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 977-86.
2. Anonymous. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998; 352: 854-65.
3. Anonymous. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998; 352: 837-53.
4. National Diabetes Data Group. Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. Diabetes 1979; 28: 1039-57.
5. World Health Organization Expert Committee on Diabetes Mellitus. Diabetes mellitus: Report of a WHO Study Group. Geneva, 1985.
6. McCance DR, Hanson RL, Charles MA et al. Comparison of tests for glycated haemoglobin and fasting and two hour plasma glucose concentrations as diagnostic methods for diabetes [published erratum appears in BMJ 1994 Oct; 309 (6958): 841]. BMJ 1994; 308: 1323-28.
7. Engelgau MM, Thompson TJ, Herman WH et al. Comparison of fasting and 2-hour glucose and HbA1c levels for diagnosing diabetes. Diagnostic criteria and performance revisited. Diabetes Care 1997; 20: 785-91.
8. Hanson RL, Nelson RG, McCance DR et al. Comparison of screening tests for non-insulin-dependent diabetes mellitus. Arch Intern Med 1993; 153: 2133-40.
9. The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 1997; 20: 1183-97.
10. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 1998; 15: 539-53.
11. Mannucci E, Bardini G, Ognibene A, Rotella CM. Comparison of ADA and WHO screening methods for diabetes mellitus in obese patients. Diabet Med 1999; 16 (Abstract): 579-85.
12. Tominaga M, Eguchi H, Manaka H, Igarashi K, Kato T, Sekikawa A. Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose. Diabetes Care 1999; 22: 920-4.
13. Dooley SL, Metzger BE, Cho NH. Gestational diabetes mellitus. Influence of race on disease prevalence and perinatal outcome in a US population. Diabetes 1991; 40 Suppl 2: 25-9.
14. Metzger BE, Coustan DR. Summary and recommendations of the fourth international workshop-conference on gestational diabetes mellitus. Diabetes Care 1998; 21 Suppl 2, B161-B167.
15. Magee MS, Walden CE, Benedetti TJ, Knopp RH. Influence of diagnostic criteria on the incidence of gestational diabetes and perinatal morbidity. JAMA 1993; 269: 609-15.
16. Sermer M, Naylor CD, Gare DJ et al. Impact of increasing carbohydrate intolerance on maternal-fetal outcomes in 3637 women without gestational diabetes. The Toronto Tri-Hospital Gestational Diabetes Project. Am J Obstet Gynecol 1995; 173: 146-56.
17. Coustan DR, Imarah J. Prophylactic insulin treatment of gestational diabetes reduces the incidence of macrosomia, operative delivery, and birth trauma. Am J Obstet Gynecol 1984; 150: 836-42.
18. Coustan DR. Gestational diabetes. Diabetes Care 1993; 16 Suppl. 3: 8-15.
19. Mestman JH, Anderson GV, Guadalupe V. Follow-up study of 360 subjects with abnormal carbohydrate metabolism during pregnancy. Obstet Gynecol 1972; 39: 421-5.
20. Tallarigo L, Giampietro O, Penno G, Miccoli R, Gregori G, Navalesi R. Relation of glucose tolerance to complications of pregnancy in nondiabetic women. N Engl J Med 1986; 315: 989-92.
21. Langer O, Brustman L, Anyaegbunam A, Mazze R. The significance of one abnormal glucose tolerance test value on adverse outcome in pregnancy. Am J Obstet Gynecol 1987; 157: 758-63.
22. Eriksson UJ. Lifelong consequences of metabolic adaptations in utero? [comment]. Diabetologia 1996; 39: 1123-5.
23. Purdy LP, Metzger BE. Influences of the intrauterine metabolic environment on adult disease: what may we infer from size at birth? Diabetologia 1996; 39: 1126-30.
24. Silverman BL, Metzger BE, Cho NH, Loeb CA. Impaired glucose tolerance in adolescent offspring of diabetic mothers. Relationship to fetal hyperinsulinism. Diabetes Care 1995; 18: 611-7.
25. Alberti K, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications part 1: Diagnosis and classification of diabetes mellitus - Provisional report of a WHO consultation. Diabet Med 1998; 15: 539-53.
26. Kilpatrick ES, Maylor PW, Keevil BG. Biological variation of glycated hemoglobin. Implications for diabetes screening and monitoring. Diabetes Care 1998; 21: 261-4.
27. Simon D, Senan C, Balkau B, Saint-Paul M, Thibult N, Eschwege E. Reproducibility of HbA1c in a healthy adult population: The Telecom Study. Diabetes Care 1999; 22: 1361-3.
28. Perucchini D, Fischer U, Spinas GA, Huch A, Huch R, Lehmann R. Fasting plasma glucose to screen for gestational diabetes mellitus: A population based study. Brit Med J 1999; 319: 812-5.
29. Reichelt AJ, Spichler ER, Branchtein L, Nucci LB, Franco LJ, Schmidt MI. Fasting plasma glucose is a useful test for the detection of gestational diabetes. Brazilian Study of Gestational Diabetes (EBDG) Working Group. Diabetes Care 1998; 21: 1246-9.
30. Sacks DA, Greenspoon JS, Fotheringham N. Could the fasting plasma glucose assay be used to screen for gestational diabetes? J Reprod Med 1992; 37: 907-9.
31. Orchard TJ, Forrest KY, Ellis D, Becker DJ. Cumulative glycemic exposure and microvascular complications in insulin-dependent diabetes mellitus. The glycemic threshold revisited. Arch Intern Med 1997; 157: 1851-6.
32. Garancini MP, Gobbi C, Errera A, Sergi A, Gallus G. Age-specific incidence and duration of known diabetes. The Cremona Study. Diabetes Care 1996; 19: 1279-82.
33. Harris MI, Flegal KM, Cowie CC et al. Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in US adults. The Third National Health and Nutrition Examination Survey, 1988-1994. Diabetes Care 1998; 21: 518-24.
34. Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998; 339: 229-34.
35. Wood D, De BG, Faergeman O, Graham I, Mancia G, Pyorala K. Prevention of coronary heart disease in clinical practice: recommendations of the Second Joint Task Force of European and other Societies on Coronary Prevention. Atherosclerosis 1998; 140: 199-270.
36. Anonymous. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. UK Prospective Diabetes Study Group. BMJ 1998; 317: 713-20.
37. Anonymous. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. BMJ 1998; 317: 703-13.
38. Hansson L, Zanchetti A, Carruthers SG et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the hypertension optimal treatment (HOT) randomised trial. Lancet 1998; 351: 1755-62.
39. Anonymous. Cost effectiveness analysis of improved blood pressure control in hypertensive patients with type 2 diabetes: UKPDS 40. UK Prospective Diabetes Study Group. BMJ 1998; 317: 720-6.
40. Pyorala K, Pedersen TR, Kjekshus J, Faergeman O, Olsson AG, Thorgeirsson G. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S) [published erratum appears in Diabetes Care 1997 Jun; 20 (6): 1048]. Diabetes Care 1997; 20: 614-20.
41. Goldberg RB, Mellies MJ, Sacks FM et al. Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: subgroup analyses in the cholesterol and recurrent events (CARE) trial. The Care Investigators. Circulation 1998; 98: 2513-9.
42. Gaede P, Vedel P, Parving HH, Pedersen O. Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: the Steno type 2 randomised study. Lancet 1999; 353: 617-22.
43. Carpenter MW, Coustan DR. Criteria for screening tests for gestational diabetes. Am J Obstet Gynecol 1982; 144: 768-73.